Hologic Inc (HOLX)

Official site

MEDICAL INSTRUMENTS & SUPPLIES

$76.01

+0.00 (+0.00%)

Last updated: Apr 07, 2026 at 5:00 PM ET

Earnings

Performance (10Y)

Beat Rate

92%(34/37)

Avg Surprise

+14.65%

Upcoming Estimates

Period ending Jun 30, 2026

EPS Consensus$1.12

Range$1.09 - $1.18

10 analysts

EPS RevisionsNo revisions (7d)

30d

EPS Estimate DriftChange to current

90d ago$1.15-2.6%

60d ago$1.13-0.8%

30d ago$1.11+1.3%

7d ago$1.11+1.3%

Current$1.12

Revenue Consensus

$1.1B

Range$1.0B - $1.1B

6 analysts

Period ending Sep 30, 2026

EPS Consensus$1.16

Range$1.06 - $1.35

15 analysts

Revenue Consensus

$1.1B

Range$1.0B - $1.1B

14 analysts

Last 12 of 37 reported quarters and 2 upcoming estimates

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Sep 30, 2026Sep 26EST	-	$1.16	$1.06 - $1.35	-	-	15	-	-
Jun 30, 2026Jun 26EST	-	$1.12	$1.09 - $1.18	-	-	10	1 3 30d	-
Dec 31, 2025Dec 25 Reported Jan 29, 2026Reported Jan 29	$1.04	$1.10	$1.04 - $1.18	-5.45%	Miss	12	5 0 30d	+1.0%
Sep 30, 2025Sep 25 Reported Nov 3, 2025Reported Nov 3	$1.13	$1.10	$1.05 - $1.11	+2.73%	Beat	19	0 2 30d	+11.9%
Jun 30, 2025Jun 25 Reported Jul 30, 2025Reported Jul 30	$1.08	$1.05	$1.04 - $1.06	+2.86%	Beat	16	0 14 30d	+1.9%
Mar 31, 2025Mar 25 Reported May 1, 2025Reported May 1	$1.03	$1.02	$1.00 - $1.03	+0.98%	Beat	16	1 12 30d	+0.0%
Dec 31, 2024Dec 24 Reported Feb 5, 2025Reported Feb 5	$1.03	$1.02	$1.00 - $1.03	+0.98%	Beat	15	2 2 30d	+5.1%
Sep 30, 2024Sep 24 Reported Nov 4, 2024Reported Nov 4	$1.01	$1.01	$0.94 - $1.03	+0.00%	Beat	19	2 0 30d	+13.5%
Jun 30, 2024Jun 24 Reported Jul 29, 2024Reported Jul 29	$1.06	$1.01	$0.99 - $1.04	+4.95%	Beat	15	No revisions (30d)	+14.0%
Mar 31, 2024Mar 24 Reported May 2, 2024Reported May 2	$1.03	$0.98	$0.96 - $1.00	+5.10%	Beat	14	1 0 30d	-2.8%
Dec 31, 2023Dec 23 Reported Feb 1, 2024Reported Feb 1	$0.98	$0.95	$0.92 - $0.98	+3.16%	Beat	14	4 0 30d	-8.4%
Sep 30, 2023Sep 23 Reported Nov 9, 2023Reported Nov 9	$0.89	$0.84	$0.77 - $0.88	+5.95%	Beat	19	0 1 30d	+8.5%
Jun 30, 2023Jun 23 Reported Jul 31, 2023Reported Jul 31	$0.93	$0.89	$0.85 - $0.94	+4.49%	Beat	16	1 0 30d	-2.1%
Mar 31, 2023Mar 23 Reported May 1, 2023Reported May 1	$1.06	$0.88	$0.83 - $0.93	+20.45%	Beat	16	No revisions (30d)	-48.8%

Key Metrics

Valuation
P/E Ratio	N/A	EV/EBITDA	N/A
Price/FCF	N/A	FCF Yield	N/A
Profitability
Profit Margin	N/A	Operating Margin	N/A
ROE	N/A	ROIC	N/A
Financial Health
Debt/Equity	N/A	Interest Coverage	N/A
Current Ratio	N/A	Quick Ratio	N/A
Trading Statistics
Beta	N/A	Avg Volume	N/A
52-Week High	N/A	52-Week Low	N/A

Technical Indicators Dashboard

Moving Averages

SMA 10$75.68

SMA 20$75.49

SMA 50$75.30

SMA 200$71.34

EMA 10$75.71

EMA 20$75.58

EMA 50$75.28

EMA 200$70.84

MACD

Line: 0.15Signal: 0.11Hist: 0.04

ADX

ADX: 20.6+DI: 27.6-DI: 10.1

Aroon & PSAR

Aroon Up96.0

Aroon Down40.0

PSAR$75.48

Bollinger Bands

Upper Band$76.03

Lower Band$74.95

%B Position142%(Upper)

Band Width0.98

RSI (14-Day)

Neutral

68.7

Momentum Oscillators

Stoch %K90.6

Stoch %D84.7

Williams %R-5.8

ROC (10d)0.5%

Momentum0.37

CCI (20d)174.7

MFI (14d)94.4

Volatility Measures

ATR (14d)$0.21(0.3%)

StdDev (20d)0.27

Hist Vol2.9%(Low)

Volume Flow

VWAP$76.01

OBV155.2M

AD Line-107.2M

CMF (20d)-0.457

Volume Metrics

Avg Vol (20d)8.1M

Vol RatioN/A

VWMA (20d)$75.77

Pivot Points

R3$76.12

R2$76.10

R1$76.05

Pivot Point$76.03

S1$75.98

S2$75.96

S3$75.91

Advanced Oscillators

TSI21.07

Ultimate Osc59.8

KST4.83

Financial Data

Quarter	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023	Mar 2023
Total Revenue	$1.05B	$1.05B	$1.02B	$1.01B	$1.02B	$988.00M	$1.01B	$1.02B	$1.01B	$945.30M	$984.40M	$1.03B
Cost of Revenue	$461.40M	$466.10M	$447.20M	$628.00M	$441.30M	$430.30M	$451.10M	$475.50M	$445.60M	$445.00M	$616.90M	$440.70M
Gross Profit	$586.40M	$583.50M	$576.60M	$377.30M	$580.50M	$557.70M	$560.30M	$542.30M	$567.50M	$500.30M	$367.50M	$585.80M

Operating Expenses	$349.40M	$346.60M	$322.00M	$384.30M	$350.70M	$327.70M	$316.30M	$331.90M	$369.30M	$367.80M	$366.10M	$313.70M
R&D	$60.50M	$65.00M	$61.40M	$61.50M	$60.30M	$67.30M	$64.10M	$74.60M	$66.80M	$72.90M	$72.60M	$74.00M
SG&A	$127.80M	$114.80M	$99.10M	$119.70M	$115.70M	$103.20M	$94.00M	$100.40M	$111.80M	$92.90M	$90.20M	$100.80M
Operating Income	$237.00M	$236.90M	$254.60M	$-7,000,000	$229.80M	$230.00M	$244.00M	$210.40M	$198.20M	$132.50M	$1.40M	$272.10M

Interest Income	$19.70M	$18.90M	$16.40M	$14.90M	$24.20M	$28.40M	$28.40M	$24.00M	$27.90M	$35.90M	$32.50M	$31.50M
Interest Expense	$27.60M	$28.60M	$28.90M	$29.10M	$30.50M	$31.90M	$31.90M	$32.30M	$26.00M	$28.10M	$27.70M	$27.20M
Income Before Tax	$229.70M	$227.20M	$235.00M	$-28,500,000	$247.50M	$221.60M	$240.70M	$211.50M	$191.30M	$145.60M	$12.10M	$279.30M
Income Tax Expense	$50.60M	$40.00M	$40.10M	$-11,100,000	$46.50M	$43.00M	$46.20M	$41.60M	$-55,200,000	$55.00M	$52.60M	$60.80M

Net Income	$179.10M	$187.20M	$194.90M	$-17,400,000	$201.00M	$178.60M	$194.50M	$169.90M	$246.50M	$90.60M	$-40,500,000	$218.50M

EBITDA	$307.20M	$316.40M	$317.60M	$61.90M	$327.80M	$299.70M	$316.50M	$293.50M	$277.80M	$213.30M	$88.50M	$355.80M
EBIT	$237.60M	$236.90M	$247.50M	$-14,300,000	$253.80M	$225.10M	$244.20M	$219.80M	$189.40M	$137.80M	$7.30M	$275.00M

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about HOLX

News

CEMENTOS PACASMAYO SAA Amended Tender Offer Recommendation

Cementos Pacasmayo S.A.A. (CPAC) has filed an Amendment No. 1 to its Schedule 14D-9, amending and supplementing a previously filed solicitation/recommendation statement regarding a tender offer by Inversiones ASPI S.A....

Stock Titan•Nov 3, 2026 6:12 AM ET11/3/26•Neutral

Labcorp Holdings (LH) Following Earnings And Higher Guidance Is It Fully Valued

Labcorp Holdings (LH) is under scrutiny after reporting strong Q3 earnings, upgraded full-year revenue guidance, and new collaborations...

Simply Wall St•Nov 1, 2026 4:51 PM ET11/1/26•Neutral

Thinking Out of the ‘Box’: NGS Platform Makers Eye Data Biz Amidst AI Biology Gold Rush

Next-generation sequencing (NGS) platform manufacturers are reportedly looking beyond their traditional hardware business to capitalize on the growing demand for data in the artificial intelligence (AI) biology sector....

GenomeWeb•Oct 28, 2026 5:45 AM ET10/28/26•Somewhat-Bullish

Cementos Pacasmayo S.A.A. Q3 Earnings Call Highlights

Cementos Pacasmayo S.A.A. (CPAC) reported strong third-quarter results with increased revenue, earnings, and margins, driven by higher cement demand, strategic pricing, and cost efficiencies. The company's CEO...

TradingView•Oct 27, 2026 3:09 PM ET10/27/26•Neutral

Davion Healthcare Announces US$25 Million Acquisition of Humaskan Medical Technology IP

Davion Healthcare Plc has acquired the intellectual property for two medical technologies, WoundSkan and Spektra Lateral Flow Test, from Humaskan Ltd for US$25 million. This acquisition...

Yahoo Finance UK•Oct 27, 2026 3:17 AM ET10/27/26•Neutral

HOLX Competitors

Company	Ticker
Medpace Holdings Inc	MEDP
Ascendis Pharma AS	ASND
EXACT Sciences Corporation	EXAS
Revvity Inc.	RVTY
Zimmer Biomet Holdings Inc	ZBH
Exelixis Inc	EXEL
Viatris Inc	VTRS
Neurocrine Biosciences Inc	NBIX

Sector: Healthcare

HOLX Bull Case vs Bear Case

Bull case

HOLX beat EPS estimates in 75.0% of its last 8 reported quarters.

HOLX Earnings: Beat Rate and Next Report

Beat rate: 6 of 8 quarters (75.0%)
Average surprise: 1.5%
EPS estimate (fiscal period ending Jun 30, 2026): $1.12
Estimate revisions (30 days, fiscal period ending Jun 30, 2026): 1 up, 3 down

HOLX Earnings Call

The latest HOLX earnings call transcript on file is labeled 2025Q3.

Read the 2025Q3 transcript

HOLX ETF Holders

GNG tracks 3 ETFs that hold HOLX. The largest weights:

BlackRock Health Sciences Trust (BME), 0.17% of the fund
Schwab U.S. Broad Market ETF (SCHB), 0.04% of the fund
Fidelity 500 Index Fund (FXAIX), 0.03% of the fund

Open the ETF Stock Exposure tool for HOLX

See insider activity

Frequently Asked Questions About HOLX

Does HOLX pay dividends?

Hologic Inc (HOLX) does not currently pay a regular dividend.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In